GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Coretech 5 (XPAR:MLCOT) » Definitions » Net Income From Continuing Operations

Coretech 5 (XPAR:MLCOT) Net Income From Continuing Operations : €-0.06 Mil (TTM As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Coretech 5 Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Coretech 5's net income from continuing operations for the six months ended in Dec. 2022 was €-0.06 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2022 was €-0.06 Mil.

Coretech 5 Net Income From Continuing Operations Historical Data

The historical data trend for Coretech 5's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coretech 5 Net Income From Continuing Operations Chart

Coretech 5 Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only -0.15 -0.21 -0.12 -0.16 -0.06

Coretech 5 Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only -0.15 -0.21 -0.12 -0.16 -0.06

Coretech 5 Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2022 was €-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coretech 5 (XPAR:MLCOT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Coretech 5 (XPAR:MLCOT) » Definitions » Net Income From Continuing Operations
Comparable Companies
XPAR:ALRPD ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
5 rue de Castiglione, Paris, FRA, 75 001
Website
https://www.coretech5.com
Coretech 5 Formerly Gour Medical AG is a pharmaceutical company. It develops and markets veterinary medicines and specialist pet. Its products include food supplements or nutraceuticals or related medical devices. The products are dedicated to the treatment of pain, allergies, behavioral disorders and improvement of quality of life. It sells its product under the brand Weedley.

Coretech 5 (XPAR:MLCOT) Headlines

No Headlines